Topiramate Works for Patients with Epilepsy and Migraines

Topiramate Works for Patients with Epilepsy and Migraines

topiramateTopiramate CAS# 97240-79-4, is also known as the brand name medication Topamax. Marketed by Janssen, Topamax has a patent expiration of October 13, 2015. As an effectual and reliable medication to treat patients with both epilepsy and migraines, topiramate is known for it’s effectiveness as monotherapy or adjunctive therapy for the treatment of epilepsy. Tablets of topiramate are available in strengths of 25, 50, 100 and 200 milligrams. Sprinkle capsules are offered in both 15 and 25 milligram doses. As monotherapy or adjunctive therapy, topiramate is therapeutic for patients with partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. The typical dosage of topiramate for migraine sufferers is a prophylaxis treatment 100 milligrams per day, administered in two divided doses. For patients with epilepsy the treatment is individualized, however base studies have indicated that as monotherapy for patients ages 10 and older the recommended daily dose  of topiramate is 400 milligrams daily, dispensed in two divided doses. Clinical trial results showed that almost 60% of patients randomized to receive this 400 milligram/daily divided dose achieved efficacy. The dosing is done on a titrated schedule, however, and daily doses exceeding 1,600 milligrams have not been studied.

Adverse effects of topiramate  may include  loss of appetite, diarrhea, weight loss, nausea, a tingling sensation in the arms and legs, anxiety and upper respiratory tract infections.  These side effects may not occur with all patients, and for many people the benefits surely outweigh the potential side effects of topiramate. In American there is an estimated 30 million people who suffer from migraines, and less than half of these patients are properly diagnosed with this debilitating condition. For patients with epilepsy, the use of topiramate is integral to their quality of life and safety. According to the Epilepsy Foundation, epilepsy affects nearly 3 million Americans and 50 million people worldwide.

iheadache-appCurrent research involves clinical trials to determine the benefits of treating patients with cluster headaches, essential tremors and even alcohol dependence with topiramate. Patients experiencing headaches that they believe to be migraines are advised to keep track of their migraines, and report their findings to their doctor. Some patients even choose to do this with their iPhones – with the IHeadache app. This app can help patients enduring these life affecting migraine episodes to easily record when they have these episodes, as well as the factors preceding them. LGM Pharma provides the topiramate API for research and development purposes.


Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service